Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy

To identify potential early biomarkers of treatment response and immune-related adverse events (irAE), a pilot immune monitoring study was performed in stage IV melanoma patients by flow cytometric analysis of peripheral blood mononuclear cells (PBMC). Overall, 17 patients were treated with either n...

Descripción completa

Detalles Bibliográficos
Autores principales: Reschke, Robin, Gussek, Philipp, Boldt, Andreas, Sack, Ulrich, Köhl, Ulrike, Lordick, Florian, Gora, Thomas, Kreuz, Markus, Reiche, Kristin, Simon, Jan-Christoph, Ziemer, Mirjana, Kunz, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348898/
https://www.ncbi.nlm.nih.gov/pubmed/34360781
http://dx.doi.org/10.3390/ijms22158017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348898/
https://www.ncbi.nlm.nih.gov/pubmed/34360781
http://dx.doi.org/10.3390/ijms22158017

Ejemplares similares